Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke

Stroke

Volumn 29, Issue 11, 1998, Pages 2261-2267

  Kristensen, Bo ^a   Malm, Jan ^b   Nilsson, Torbjörn K ^b   Hultdin, Johan ^b   Carlberg, Bo ^b   Olsson, Tommy ^b  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Fibrinogen; Fibrinolysis; Plasminogen activators; Stroke, ischemic; Young adults

Indexed keywords

CHOLESTEROL; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTERY DISSECTION; ARTICLE; ATHEROMA; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART RIGHT LEFT SHUNT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031786326     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.11.2261     Document Type: Article

References (47)

1. Bogousslavsky J, Philippe P. Ischemic stroke in patients under age 45. Neurol Clin. 1992;10:113-124.
2. Carolei A, Marini C, Ferranti E, Massimiliano P, Fieschi C. A prospective study of cerebral ischemia in the young: analysis of pathogenic determinants. Stroke. 1993;24:362-367.
3. Mas JL. Patent foramen ovale, atrial septum aneurysm and ischemic stroke in young adults. Eur Heart J. 1994;15:446-449.
4. Edzard E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
5. Hamsten A, DeFaire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
6. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
7. Jansson JH, Olofsson BO, Nilsson JK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation. 1993;88:2030-2034.
8. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
9. Cortellaro M, Cofrancesco E, Bochetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study: the PLAT Group. Arterioscler Thromb. 1993;13:1412-1417.
10. Thompsom SG, Kienast J, Pyke SD, Haverkate F, Van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
11. Tengborn L, Larsson SA, Hedner U, Nilsson IM. Coagulation studies in children and young adults with cerebral ischemic episodes. Acta Neurol Scand. 1981;63:351-361.
12. Baumgartner C, Huber K, Holzner F, Zeiler K, Auff E, Binder BR. Untersuchung zur frage von persistierenden veränderungen der fibrinolyseparameter t-PA und PAI bei patienten nach juvenilen ischämischem cerebralem insult. Klin Wochenschr. 1988;66:1110-1115.
13. Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost. 1997;77:466-471.
14. Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease, I: abnormalities in factor VIII and antithrombin. Thromb Res. 1982;26: 183-192.
15. Chancellor AM, Glasgow GL, Ockelford PA, Johns A, Smith J. Etiology, prognosis and hemostatic function after cerebral infarction in young adults. Stroke. 1989;20:477-482.
16. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompsom SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group: European Concerted Action on Thrombosis and Disabilities. Circulation. 1996;94:2057-2063.
17. Eliasson M, Evrin P-V, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: the Northern Sweden MONICA Study. J Clin Epidemiol. 1994;47:513-524.
18. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in Northern Sweden. Stroke. 1997;28: 1702-1709.
19. WHO Study Group on Diabetes Mellitus. Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985. World Health Organization Technical Report, Series 727.
20. Johnson CJ, Kittner SJ, McCarter RJ, Sloan MA, Stem BJ, Buchholz D, Price TR. Interrater reliability of an etiologic classification of ischemic stroke. Stroke. 1995;26:46-51.
21. Rånby M, Sundell IB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost. 1989;62:917-922.
22. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Bucht G, Winblad B. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem. 1986;32:2160-2165.
23. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res. 1983;31:427-436.
24. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem. 1982;28:1356-1358.
25. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;342:940-943.
26. Lindgren A, Lindoff C, Norrving B, Åstedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996;27:1066-1071.
27. Catto AJ, Carter AM, Stickland MH, Bamford J, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promotor polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730-734.
28. Nilsson TK. Analysis of factors affecting tissue plasminogen activator inhibitor activity and antigen concentration before and after venous occlusion in 123 patients. Clin Chem Enzymol Commun. 1989;1:335-341.
29. Wall U, Jern C, Bergbrant A, Jern S. Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension. 1995; 26:796-800.
30. Eliasson M, Evrin P-E, Lundblad D, Asplund K, Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen: a population study. Fibrinolysis. 1993;7:316-323.
31. DeGaetano G, Carriero MR, Cerletti C, Mussoni L. Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochem Pharmacol. 1986;35:3147-3150.
32. Hammouda MW, Moroz LA. Aspirin and venous occlusion: effects on blood fibrinolytic activity and tissue-type plasminogen activator levels. Thromb Res. 1986;42:73-82.
33. Keber I, Jereb M, Keber D. Aspirin decreases fibrinolytic potential during venous occlusion but not during acute physical activity. Thromb Res. 1987;46:205-212.
34. Grulich-Henn J, Loechelt K, Speiser W, Muller-Berghaus G. Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy. Blut. 1989;58:39-43.
35. Haffner SM. Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl. 1997;15:S25-S30.
36. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
37. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese objects. Metabolism. 1986;35:250-253.
38. Sundell B, Nilsson TK, Nygren C, Hallmans G, Helsten G, Dahlén GH. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Sweden population. Atherosclerosis. 1989;80:9-16.
39. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851-1855.
40. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol. 1998;18:84-91.
41. Eliasson M, Jansson JH, Nilsson P, Asplund K. Increased level of tPA antigen in essential hypertension. J Hypertens. 1997;15:349-356.
42. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miyra M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2:800-803.
43. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
44. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
45. Lee AJ, Lowe GDO, Woodward M, Tunnstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Healthy Study. Br Heart J. 1993;69:338-342.
46. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ. 1991;303:605-609.
47. Warlow CP, Rennie JAN, Ogston D, Douglas AS. Platelet adhesiveness and fibrinolysis after recent cerebrovascular accidents and their relationship with subsequent deep venous thrombosis of the legs. Thromb Haemost. 1976;36:127-132.